Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing. The oversubscribed financing round was backed by more than 15 ...

Cell therapy is a field rife with innovation, but most of the novel therapies being developed fall into one of two basic categories: autologous cell therapies, which involve removing a patient’s ...

Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to turn its focus toward autoimmune diseases. The move isn’t shocking ...

CAR-T cell therapy involves extracting a patient's T-cells, modifying them to recognize cancer cells, and then reinfusing them into the patient where they target cancer cells throughout the body.

Drexel's Master of Science in Biomedicine and Cell and Gene Therapy program offers a unique graduate-level opportunity for students at the intersection of medicine and bioengineering. An ever-evolving ...

Known as Chimeric Antigen Receptor T-cell therapy, or CAR T-cell therapy for short, it has proven highly effective for blood cancers, but has not yet been able to make the leap to treating solid ...

A study published in The Lancet Haematology has reported a 73% response rate for CAR T-cell therapy among patients with certain blood cancers. The clinical trials were conducted by researchers ...

Known as 'CAR T-cell therapy', the treatment involves modifying genes in one's T-cells -- a type of immune cells -- to help fight cancer. The study looked at patients with leukaemia, which occurs ...

Susan Galbraith, executive vice-president of oncology R&D at AstraZeneca, said the deal “has the potential to transform cell therapy and will enable us to scale these innovative treatments so ...